VCAR-33 (Vor Biopharma)

N/A

Report date: 2025/07/30 20:01:17

Base Information

Drug NameVCAR-33 (Vor Biopharma)
Drug Alias NameAnti-CD33 CAR T Cell Therapy (Vor Biopharma)Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy(Vor Biopharma)Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells(Vor Biopharma)VCAR-33VCAR33
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-Myeloid cell surface antigen CD33
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVor Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVor Biopharma Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A